Navigation Links
Osteotech Receives FDA Clearance for Plexur M(TM) Biocomposite

EATONTOWN, N.J., March 4 /PRNewswire-FirstCall/ -- Osteotech, Inc. (Nasdaq: OSTE), a leader in the emerging field of biologic solutions for regenerative medicine, announced today that the Food and Drug Administration ("FDA") has cleared its 510(k) submission for its Plexur M(TM) Biocomposite. Adapting the Company's proprietary Plexur(R) Technology, Plexur M(TM) is intended for use in filling bony voids or gaps of the skeletal system that are not intrinsic to the stability of the bony structure. During the healing process, Plexur M(TM) is remodeled and replaced by host bone.

Plexur M(TM) is a uniquely flexible biomaterial composed of mineralized cortical fibers bound in a resorbable polymer. When heated, this biocomposite becomes moldable and pliable allowing a surgeon numerous options for use during surgery. During the cooling process, Plexur M(TM) hardens providing a versatile porous scaffold to assist in regeneration of damaged and diseased bones. It is an ideal medium for placing screws with no cracking or resultant particulate shedding and can be reamed and reverse-reamed without dislodging the graft or damaging the surrounding bone. Plexur M(TM) uses proprietary processing steps that have been shown to inactivate viruses and is terminally sterilized.

Sam Owusu-Akyaw, Osteotech's President and Chief Executive Officer, stated, "We are very pleased to be able to introduce the Plexur M(TM) Biocomposite. Our internal team has done an excellent job to develop this product and receive FDA clearance for orthopedic applications. We anticipate filing an additional 510(k) submission for the use of Plexur M(TM) in spinal applications in the first part of the second quarter. We plan to continue our research and development activities under our Plexur(R) Technology and expect to deliver additional innovative products in the future."

Mr. Owusu-Akyaw concluded, "Plexur M(TM) will be positioned to compete against osteoconductive and settable synthetic bone void fillers. We expect to begin distributing Plexur M(TM) in the next three to six months to centers of key opinion leaders to allow for the gathering of human clinical information. Osteotech will host hands-on sessions to demonstrate the Plexur M(TM) on March 5 and 6, 2008 at the American Academy of Orthopedic Surgeons 2008 Annual Meeting in San Francisco, California."

The Plexur(R) Technology is designed to utilize bone tissue for procedure- specific surgical applications in combination with a wide variety of polymers. On a worldwide basis, Osteotech currently controls 33 patents and over 65 pending patent applications covering the Plexur(R) Technology for human and xenograft bone tissue.

Osteotech, Inc., headquartered in Eatontown, New Jersey, is a global leader in providing OsteoBiologic solutions for regenerative medicine to support surgeons and their patients in the repair of the musculoskeletal system through the development of innovative therapy-driven products that alleviate pain, promote biologic healing and restore function. For further information regarding Osteotech or this press release, please go to Osteotech's website at

Certain statements made throughout this press release that are not historical facts contain forward-looking statements (as such are defined in the Private Securities Litigation Reform Act of 1995) regarding the Company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the Company's ability to develop and introduce new products, differences in anticipated and actual product and service introduction dates, the ultimate success of those products in the marketplace, the continued acceptance and growth of current products and services, the impact of competitive products and services, the availability of sufficient quantities of suitable donated tissue and the success of cost control and margin improvement efforts. Certain of these factors are detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission. All information in this press release is as of March 4, 2008 and the Company does not intend to update this information.

SOURCE Osteotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Osteotech to Present at the Canaccord Adams Small-Cap Orthopedics Conference in San Francisco
2. Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007
3. Osteotech Announces Fourth Quarter and Full Year Earnings Release and Conference Call Schedule
4. Osteotech to Present at Sidoti Conference in San Francisco
5. Osteotech to Present at Roth Capital Partners 2007 New York Investor Conference
6. Ventria Receives Friends of Education Award From Geary County School District
7. STAAR Surgical Receives Approval to Market Visian(R) Toric Implantable Collamer Lens in China
8. Actavis Receives Approval for Irinotecan Hydrochloride Injection; Extends US Portfolio with First Injectable Product
9. Kyowa Hakko Receives Not Approvable Letter from FDA for Istradefylline (KW-6002)
10. Vermillion Receives NASDAQ Notice of Non-Compliance
11. Purchase Agreement for Antibody Manufacturing Facility Receives Antitrust Clearance
Post Your Comments:
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... Global Stem Cells Group announced ... clinics in the cities of Arica and Iquique in northern Chile. The facilities are part ... offer the most advanced protocols and techniques in stem cell medicine to patients from around ...
(Date:11/30/2015)... /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), a leader in ... Business Act on Climate Pledge, alongside more than 140 companies ... Obama Administration to demonstrate an ongoing commitment to climate action ... COP21 Paris climate negotiations. ... Canada . --> BioAmber uses biotechnology to ...
(Date:11/30/2015)...  Culprits beware, a University at Albany research ... is taking crime scene fingerprint identification to a ... -->   --> Photo ... --> Halámek and his team ... concept for identifying whether a culprit is male ...
(Date:11/30/2015)... Nov. 30, 2015 /PRNewswire/ - Zenith Epigenetics Corp. ("Zenith" or ... Norman C.W. Wong to its Board of Directors to ... Zenith with a wealth of experience as co-founder of Resverlogix, ... --> --> Dr. Wong ... board of directors. Zenith,s long standing expertise in epigenetics and ...
Breaking Biology Technology:
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has ... to provide preclinical development services to the National Cancer ... SRI will provide scientific expertise, modern testing and support ... of preclinical pharmacology and toxicology studies to evaluate potential ... --> The PREVENT Cancer Drug Development Program is ...
(Date:10/29/2015)... LA JOLLA, Calif. , Oct. 29, 2015 /PRNewswire-USNewswire/ ... released a new report titled, "DNA Synthesis and Biosecurity: ... how well the Department of Health and Human Services ... was issued in 2010. --> ... advances, but it also has the potential to pose ...
(Date:10/29/2015)... Mich. , Oct. 29, 2015  Rubicon ... Genomics for U.S. distribution of its DNA library ... kit and Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX ... enable the preparation of NGS libraries for liquid ... for diagnostic and prognostic applications in cancer and ...
Breaking Biology News(10 mins):